Publications With Epilepsy Study Consortium Contributions

  1. Herman ST, Allen JC, Vogelsong B, French JA.  (2006) VNS Therapy Versus Add-on Antiepileptic Drug in Early Refractory Epilepsy: A Prospective Pilot Study. American Academy of Neurology, April 2007. Abstract # 951202.
  2. Vogelsong B, French JA, Brodie MA. Assessment of Seizure Classification in Multinational, Multicenter Antiepileptic Drug Trials. American Epilepsy Society, December 2010. Abstract.
  3. Fisher RS, Blum DE, DiVentura B Vannest J, Hixson JD, Moss R, Herman ST, Fureman BE, French JA. Seizure diaries for clinical research and practice: Limitations and future prospects. Epilepsy and Behavior, 2012 Jul;24(3):304-10.
  4. French JA, DiVentura B, Posner H, Zangrilli Z. Real-time Central Patient Review Improved Quality in Once-a-Day Trial of Pregabalin for Partial Epilepsy in Adults (A0081194). American Society for Experimental Neurotherapeutics, February 2013. Abstract.
  5. Hesdorffer DC, French JA, Posner K, DiVentura B, Pollard JR, Sperling MR, Harden CL, Krauss GL, Kanner AM. Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials. Epilepsia. 2013 May; 54 (5):879-87.
  6. Kasteleijn-Nolst Trenité DG, Biton V, French JA, Abou-Khalil B, Rosenfeld WE, DiVentura B, Moore EL, Hetherington SV, Rigdon GC. Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy. Epilepsia. 2013 Aug; 54(8):1437-43.
  7. DiVentura B, French J, Anders B, Laine D, Halvorsen M. Use of Investigator Training to Improve Seizure Classification in PREVAIL—a Phase 3, Global Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Adults with Partial-Onset Seizures. American Epilepsy Society, December 2013. Abstract.
  8. French J, Sperling J, Perucca E, Losey T, Shneker B, DiVentura B, Belkin M, Hua L, Paskavitz A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of VX-765 in Patients with Treatment-Resistant Focal Seizures. American Epilepsy Society, December 2013. Abstract.
  9. DiVentura B, French JA, Anders B, Laine D, Halvorsen M. Use of Investigator Training to Improve Seizure Classification in PREVAIL—a Phase 3, Global Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Adults with Partial-Onset Seizures. American Academy of Neurology, April 2014. Abstract.
  10. French JA, Krauss GL, Kasteleijn D, Diventura BD, Bagiella E. Effects of Marketed Antiepileptic Drugs and Placebo in the Human Photosensitivity Screening Protocol. Neurotherapeutics. http://www.ncbi.nlm.nih.gov/pubmed/24346821 2014 Apr; 11 (2):412-8.
  11. French JA, Krauss GL, Wechsler RT, Wang X, DiVentura BD, Brandt C, Trinka E, O’Brien TJ, Laurenza A, Patten A, Bibbiani F. Adjunctive Perampanel for the Treatment of Drug-Resistant Primary Generalized Tonic-Clonic (PGTC) Seizures in Patients with Idiopathic Generalized Epilepsy (IGE): A Double-Blind, Randomized, Placebo-Controlled Phase III Trial. American Epilepsy Society, December 2014. Abstract.
  12. French JA, Krauss GL, Wechsler RT, Wang X, DiVentura BD, Brandt C, Trinka E, O’Brien TJ, Laurenza A, Patten A, Bibbiani F. Adjunctive Perampanel for the Treatment of Drug-Resistant Primary Generalized Tonic-Clonic (PGTC) Seizures in Patients with Idiopathic Generalized Epilepsy (IGE): A Double-Blind, Randomized, Placebo-Controlled Phase III Trial. American Academy of Neurology, April 2015. Platform Presentation.
  13. French JA, Krauss GL, Wechsler RT, Wang X, DiVentura BD, Brandt C, Trinka E, O’Brien TJ, Laurenza A, Patten A, Bibbiani F. Adjunctive Perampanel RCT for PGTC seizures. Association of British Neurologist Congress, May 2015. Abstract 53141.
  14. French JA, DiVentura BD, Trinka E, Bibbiani F, Yang H. Secondary Screening of Patients in a Randomized Perampanel PGTCS Study Excludes 29.9% of Eligible Patients Due To Inaccurate Classification. 31st International Epilepsy Congress, September 2015. Platform Presentation.
  15. French JA, Krauss GL, Wechsler RT, Wang X, DiVentura BD, Brandt C, Trinka E, O’Brien TJ, Laurenza A, Patten A, Bibbiani F. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology 2015; Sep; 85 (11):950-7.
  16. French JA, DiVentura BD, Trinka E, Bibbiani F, Yang H. Secondary Screening of Patients in a Randomized Perampanel PGTCS Study Excludes 29.9% of Eligible Patients Due To Inaccurate Classification. American Epilepsy Society, December 2015. Perampanel Scientific Exhibit.
  17. French JA, DiVentura BD, Trinka E, Bibbiani F, Yang H. Secondary Screening of Patients in a Randomized Perampanel PGTCS Study Excludes 29.9% of Eligible Patients Due To Inaccurate Classification. American Academy of Neurology, April 2016. Poster Presentation.
  18. French JA, DiVentura BD, Trinka E, Bibbiani F, Yang H. Secondary Screening of Patients in a Randomized Perampanel PGTCS Study Excludes 29.9% of Eligible Patients Due To Inaccurate Classification. Asian & Oceanian Epilepsy Congress, Perampanel Scientific Exhibit May 2016.
  19. French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN.  Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.  Lancet. 2016 Oct 29;388(10056):2153-2163.
  20. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group.  Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085-1096.
  21. French JA, Friedman D, Wechsler R, DiVentura B, Gelfand M, Pollard J, Huie K, Vazquez B, Gong L, Cassella J, Kamemoto E.  Inhaled Alprazolam, a Potential Rescue Medication, Works Rapidly in Patients with Photosensitive Epilepsy. AAN, April 2017. Poster Presentation.
  22. Kasteleijn-Nolst Trenité D, DiVentura B, Pollard J, Krauss G, French J. Cenobamate (YKP3089) in Photosensitive Patients: Proof of Principle. American Academy of Neurology, April 2017. Poster Presentation.
  23. Kasteleijn-Nolst Trenité D, DiVentura B, Pollard J, Krauss G, French J. Cenobamate (YKP3089) in Photosensitive Patients: Proof of Principle.  American Academy of Neurology, April 2018. Poster Presentation.
  24. Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds D, DiVentura B, Abou-Khalil B, Gelfand M, Pollard J, Hogan R, Krauss G, Sperling M, Vazquez B, Wechsler R, Friedman D, Butt R, French J. Photosensitive epilepsy. Neurology, April 2019. 92(15), pp. e1786-e1795. doi: 10.1212/wnl.0000000000007271
  25. Kasteleijn- Nolst Trenite D, DiVentura B, Pollard J, Krauss G, Mizne S, French J. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089).Neurology, July 2019. 93(6), pp.e559-e567. doi: 10.1212/wnl.0000000000007894
  26. Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds D, DiVentura B, Abou-Khalil B, Gelfand M, Pollard J, Hogan R, Krauss G, Sperling M, Vazquez B, Wechsler R, Friedman D, Butt R, French J. Utility of The Double-Blind Crossover Design Protocol For Proof-Of-Principle Photosensitivity Model Assessment of PF-06372865. International Society for CNS Clinical Trials and Methodology, September 2019. Abstract.
  27. Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds D, DiVentura B, Abou-Khalil B, Gelfand M, Pollard J, Hogan R, Krauss G, Sperling M, Vazquez B, Wechsler R, Friedman D, Butt R, French J. PF-06372865, an α2/3/5-subtype selective GABAA partial positive allosteric modulator has promising efficacy in the photosensitivity model. International League Against Epilepsy, October 2019. Abstract.
  28. Hesdorffer D, Martin M, Porter R, Varner J, Schultz A, Zhang Y, French J. Baseline Seizure Related Disability Assessment Scale (SERDAS) scores in an observational study of brivaracetam. American Epilepsy Society, December 2019. Abstract.
  29. Martin M, Porter R, Varner J, Schultz A, Hesdorffer D, Zhang Y, French J. Real-world study of brivaracetam in the US: an interim analysis. American Epilepsy Society, December 2019. Abstract.
  30. French J, Hesdorffer D, Porter R, Varner J, Schultz A, Zhang Y, Martin M. Baseline Seizure Related Disability Assessment Scale (SERDAS) scores in an observational study of brivaracetam. American Academy of Neurology, April 2020. Abstract – virtual platform.
  31. Martin M, Porter R, Varner J, Schultz A, Hesdorffer D, Zhang Y, French J. Real-world study of brivaracetam in the US: an interim analysis. American Academy of Neurology, April 2020. Abstract – virtual platform.